These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7327760)

  • 1. Combined hemodialysis-hemoperfusion treatment reduces the time of substitutive therapy in chronic uremia.
    Stefoni S; Feliciangeli G; Coli L; Scolari MP; Bonomini V
    Int J Artif Organs; 1981 Jul; 4(4):186-91. PubMed ID: 7327760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentric experience with combined hemodialysis/hemoperfusion in chronic uremia.
    Bonomini V; Stefoni S; Casciani CU; Taccone Gallucci M; Albertazzi A; Cappelli P; Mioli V; Boggi R; Mastrangelo F; Rizzelli S
    Contrib Nephrol; 1982; 29():133-42. PubMed ID: 7075212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies on the effect of hemoperfusion and hemodialysis on the elimination of some uremic toxins.
    Trznadel K; Walasek L; Kidawa Z; Lutz W
    Clin Nephrol; 1978 Dec; 10(6):229-31. PubMed ID: 729215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of combined hemodialysis/hemoperfusion in chronic uremia.
    Stefoni S; Feliciangeli G; Colì L; Prandini R; Bonomini V
    Contrib Nephrol; 1982; 29():123-32. PubMed ID: 6804167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemoperfusion in reduced-time programmes for chronic uremia. Long-term results.
    Stefoni S; Colì L; Feliciangeli G; Scolari MP; Bonomini V
    Int J Artif Organs; 1986 Sep; 9(5):297-300. PubMed ID: 3781660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Our experience with combined hemodialysis-hemoperfusion treatment in chronic uremia.
    Splendiani G; Albano V; Tancredi M; Daniele M; Pignatelli F
    Biomater Artif Cells Artif Organs; 1987; 15(1):175-81. PubMed ID: 3449135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperoxalemia in renal failure and the role of hemoperfusion and hemodialysis in primary oxalosis.
    Ahmad S; Hatch M
    Nephron; 1985; 41(3):235-40. PubMed ID: 4058624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Charcoal hemoperfusion for chronic renal failure.
    Siemsen AW; Dunea G; Mamdani BH; Guruprakash G
    Nephron; 1978; 22(4-6):386-90. PubMed ID: 740102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical assessment of combined ACAC hemoperfusion-ultrafiltration in uremia.
    Chang TM; Chirito E; Barre P; Cole C; Lister C; Resurreccion E
    Artif Organs; 1979 May; 3(2):127-31. PubMed ID: 533395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia.
    Winchester JF; Ratcliffe JG; Carlyle E; Kennedy AC
    Kidney Int; 1978 Jul; 14(1):74-81. PubMed ID: 682427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAPD plus hemoperfusion once a week for end stage renal disease.
    Capodicasa G; De Santo NG; Galione A; Bellavia C; Annaloro R; Vaccaro F; Picone F; Vinti V; Davi G; Rapisarda LM; Giordano C
    Int J Artif Organs; 1982 May; 5(3):125-9. PubMed ID: 7107045
    [No Abstract]   [Full Text] [Related]  

  • 12. The optimal timing of hemoperfusion component in combined hemodialysis-hemoperfusion treatment for uremic toxins removal.
    Li J; Li D; Xu Y; Wang A; Xu C; Yu C
    Ren Fail; 2015 Feb; 37(1):103-7. PubMed ID: 25421427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemosorption in the therapeutic complex for renal insufficiency in children].
    Isakov IuF; Burkov IV; Drozdov VA; Mosharov OP; Osipov IuN
    Urol Nefrol (Mosk); 1980; (5):55-9. PubMed ID: 7423691
    [No Abstract]   [Full Text] [Related]  

  • 14. Routine clinical applications of hemodialysis-hemoperfusion in chronic renal failure: case reports.
    Barré PE; Gonda A; Chang TM
    Int J Artif Organs; 1986 Sep; 9(5):305-8. PubMed ID: 3023242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemoperfusion results in uremia.
    Gelfand MC; Winchester JF
    Clin Nephrol; 1979 Feb; 11(2):107-10. PubMed ID: 378488
    [No Abstract]   [Full Text] [Related]  

  • 16. Platelet thromboxane formation and BTG levels after intensive charcoal HP in uremics or regular hemodialytic treatment (RHT).
    Capodicasa G; Daví G; Picone F; Mattina A; Giannetto V; Vinti V; Vaccaro F; Strano A; De Santo NG; Giordano C
    Int J Artif Organs; 1983 Jul; 6(4):183-6. PubMed ID: 6195116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regular hemoperfusion in regular dialysis treatment. A long-term study.
    Stefoni S; Colì L; Feliciangeli G; Baldrati L; Bonomini V
    Int J Artif Organs; 1980 Nov; 3(6):348-53. PubMed ID: 7461873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chlorpropamide overdose in renal failure: management with charcoal hemoperfusion.
    Ludwig SM; McKenzie J; Faiman C
    Am J Kidney Dis; 1987 Dec; 10(6):457-60. PubMed ID: 3687936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemoperfusion in the treatment of chronic renal failure in patients on haemodialysis.
    Ryabov SI; Shostka GD; Lukichev BG; Strelko VV; Spiridonov VN; Kartel NT; Scherbitsky AB
    Int Urol Nephrol; 1984; 16(4):345-60. PubMed ID: 6535783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a new coated charcoal for hemoperfusion in uremia.
    Stefoni S; Feliciangeli G; Coli L; Bonomini V
    Int J Artif Organs; 1979 Nov; 2(6):320-3. PubMed ID: 511374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.